Journal
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.640476
Keywords
breast cancer; immunotherapy; plasmacytoid dendritic cells; prognosis; bioinformatics analysis
Categories
Funding
- National Key Research and Development Program of China [2019YFC1711000, 2017YFC1700200]
- Professor of Chang Jiang Scholars Program
- NSFC [82004003, 81520108030, 21472238]
- Shanghai Engineering Research Center for the Preparation of Bioactive Natural Products [16DZ2280200]
- Scientific Foundation of Shanghai China [13401900103, 13401900101]
- Shanghai Sailing Program [20YF1459000]
Ask authors/readers for more resources
This study found that elevated levels of plasmacytoid dendritic cells (pDC) were associated with prolonged survival outcomes in breast cancer patients, with lower mutation burden and intratumoral heterogeneity observed in the high pDC abundance group. Patients with high pDC abundance showed a more sensitive immune response and better chemotherapy outcomes, suggesting potential benefits from combination therapy.
Plasmacytoid dendritic cells (pDC) are an essential immune microenvironment component. They have been reported for crucial roles in linking the adaptive and immune systems. However, the prognostic role of the pDC in breast cancer (BRCA) was controversial. In this work, we collected large sample cohorts and did a comprehensive investigation to reveal the relationship between pDC and BRCA by multiomics data analysis. Elevated pDC levels were correlated with prolonged survival outcomes in BRCA patients. The distinct mutation landscape and lower burden of somatic copy number alterations (SCNA) and lower intratumoral heterogeneity were observed in the high pDC abundance group. Additionally, a more sensitive immune response and chemotherapies response were observed in the high pDC group, which implicates that patients with high pDC abundance can be benefited from the combination of chemotherapy and immunotherapy. In conclusion, the correlation between pDC abundance and BRCA patients' overall survival (OS) was found to be positive. We identified the molecular profiles of BRCA patients with pDC abundance. Our findings may be beneficial in aiding in the development of immunotherapy and elucidating on the precision treatment for BRCA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available